scholarly journals Bluetongue Virus Capsid Assembly and Maturation

Viruses ◽  
2014 ◽  
Vol 6 (8) ◽  
pp. 3250-3270 ◽  
Author(s):  
Bjorn-Patrick Mohl ◽  
Polly Roy
Keyword(s):  
Bluetongue Virus ◽  
Capsid Assembly ◽  
Virus Capsid

scholarly journals Invariant Polymorphism in Virus Capsid Assembly

2009 ◽  
Vol 131 (7) ◽  
pp. 2606-2614 ◽  
Author(s):  
Hung D. Nguyen ◽  
Vijay S. Reddy ◽  
Charles L. Brooks III
Keyword(s):  
Capsid Assembly ◽  
Virus Capsid

scholarly journals A Kinase Chaperones Hepatitis B Virus Capsid Assembly and Captures Capsid Dynamics in vitro

2011 ◽  
Vol 7 (11) ◽  
pp. e1002388 ◽  
Author(s):  
Chao Chen ◽  
Joseph Che-Yen Wang ◽  
Adam Zlotnick
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Capsid Assembly ◽  
Virus Capsid ◽  
B Virus

Safety, tolerability, and pharmacokinetics of the novel hepatitis B virus capsid assembly modulator GST-HG141 in healthy Chinese subjects: a first-in-human single- and multiple-dose escalation trial

2021 ◽  
Author(s):  
Cuiyun Li ◽  
Min Wu ◽  
Hong Zhang ◽  
Jiajia Mai ◽  
Lizhi Yang ◽  
...  
Keyword(s):  
Steady State ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Maximum Plasma ◽  
Capsid Assembly ◽  
Virus Capsid ◽  
B Virus ◽  
The Mean ◽  
Healthy Chinese ◽  
Chinese Subjects

Background: Hepatitis B virus capsid assembly modulators (HBV CAMs) are promising, clinically validated therapeutic agents for the treatment of chronic hepatitis B (CHB). The safety, tolerability, and pharmacokinetic (PK) profiles of GST-HG141, a novel HBV CAM, were evaluated in healthy Chinese volunteers. Method: This phase Ia study included two parts: a double-blinded, randomized, placebo-controlled single-ascending-dose (SAD) (50, 100, 200, 300, 400, or 500 mg) study comprising a food-effect investigation (300 mg), and a multiple-ascending-dose (MAD) (100 or 200 mg BID) study. Result: GST-HG141 reached the maximum plasma concentration (C max ) at 1.25–3.00 h (median T max ). The exposure exhibited a linear increase, while the mean half-life (t 1/2 ) ranged from 13.096 h to 22.121 h. The exposure of GST-HG141 (300 mg) was higher after food intake by about 2.4-fold. In the MAD study, steady-state was reached at around day 5, and the mean trough steady-state concentrations were 423 and 588 ng/mL for 50 and 100mg cohorts, respectively. The ratios of GST-HG141 accumulation were <1.5. GST-HG141 was well tolerated in healthy Chinese subjects. The rates of adverse events (AEs) in the GST-HG141 cohort did not differ from those of the placebo cohort. Conclusion: GST-HG141 was tolerated in healthy Chinese subjects. The safety and PK profiles of GST-HG141 support the further evaluation of its efficacy in individuals with CHB.

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

2019 ◽  
Vol 5 (5) ◽  
pp. 778-787 ◽  
Author(s):  
Yameng Pei ◽  
Chunting Wang ◽  
Haijing Ben ◽  
Lei Wang ◽  
Yao Ma ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
High Throughput ◽  
Capsid Assembly ◽  
Virus Capsid ◽  
B Virus

scholarly journals Irreversible growth model for virus capsid assembly

2006 ◽  
Vol 74 (3) ◽  
Author(s):  
Stephen D. Hicks ◽  
C. L. Henley
Keyword(s):  
Growth Model ◽  
Capsid Assembly ◽  
Virus Capsid
Sign in / Sign up

Export Citation Format

Share Document